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Methods: Healthy adults aged 18—60 years (n = 313) and
elderly aged >60 years (n = 173) received two injections
(1:1 ratio), 3 weeks apart, and a six-month booster dose,
of a subunit MF59-adjuvanted H5N1 (A/Vietnam/1194/2004)
inﬂuenza (clade 1) vaccine containing either 7.5g or 15g
hemagglutinin. All participants were followed for safety
assessments. Blood samples were taken before each vac-
cination, and again three weeks and six months after each
vaccination. Serum H5N1 antibody titres were assessed by
single radial hemolysis and microneutralisation assays.
Findings: Mild pain at the injection site was the most
common reaction overall and decreased with subsequent
dosing. The humoral immune response to 7.5g vaccine was
non-inferior to that of 15g. Seroprotection rates after the
second vaccination ranged from 80% to 86% as measured
by SRH and 76% to 85% as measured by MN assays across
vaccine dose and age strata. After the six-month booster,
seroprotection rates, as measured by SRH, increased in
adults and elderly in the 7.5g group from 19% and 22%
at baseline (pre-booster) to 90% and 84%, respectively,
three weeks later, and in the 15g group from 25% and
64% at baseline for adults and elderly, respectively, to
91% and 88%. Heterologous immune response against the
A/H5N1/turkey/Turkey/05 strain was detectable after the
second vaccination and the booster vaccination, with sero-
protection rate of 57—76% and 78—88% after the second and
third dose respectively.
Interpretations: Both formulations were well tolerated
and equivalent. The 7.5g met all three SRH criteria for
pandemic vaccines licensure in the EU in both adult and
elderly participants. The cross-clade immune response sug-
gests that this vaccine adjuvanted with MF 59 is appropriate
for H5N1 prepandemic vaccination programs.
doi:10.1016/j.ijid.2008.05.358
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Sydney South West Area Health Service Public Health Unit,
Sydney, Australia
Background: Universal varicella vaccination was intro-
duced as a public health initiative in Australia in November
2005, but there are no reported vaccine effectiveness stud-
ies in Australia carried out since commencement of this
programme. An outbreak of varicella infection occurred in
a childcare centre (CCC) in Sydney, Australia in Septem-
ber 2006. We used this outbreak to assess varicella vaccine
effectiveness.
Methods: Self-administered questionnaires were used to
obtain vaccination status and medical history from parents
of all children at the CCC. The parents of all children with
varicella infection were then contacted by telephone to
obtain information regarding disease severity. Children aged
<12 months or who had varicella infection prior to the out-
break were excluded. Vaccine effectiveness was calculated
using the cohort method.
Results: 112 children attended the CCC at the time of
the outbreak; 86 questionnaires were returned (response
rate 77%). Ten children were excluded from the study due to
age or previous varicella infection. 54% (41/76) of suscepti-
ble children were vaccinated at the time of the outbreak.
There were 23 cases of varicella infection (attack rate 30%);
of these, 8 (35%) had previously received the varicella vac-
cine. All cases hadmild-moderate disease. The attack rate in
the vaccinated population was 20% (8/41) compared to 43%
(15/35) in the unvaccinated population. Vaccine efﬁcacy in
this outbreak was 54%. The relative risk (RR) of mild disease
in the unvaccinated compared to the vaccinated population
was 0.94, whereas the RR of moderate to severe disease was
11.7.
Conclusion: In this outbreak, varicella vaccine did not
appear to be effective in preventing an outbreak; however
it did have a likely impact on disease severity, appar-
ently effective in preventing moderate to severe disease.
Vaccination of vulnerable populations, including catch-
up of previously missed individuals, should be strongly
encouraged to reduce severity of disease during future out-
breaks.
doi:10.1016/j.ijid.2008.05.359
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Background: Dengue disease is a major public health
problem in tropical and subtropical areas. As any of the
four serotypes of dengue virus can cause the classic or
severe hemorrhagic forms of the disease, a tetravalent
dengue vaccine is needed. Prior exposure to a ﬂavivirus
could potentially modulate the safety and immunogenicity
of a tetravalent dengue vaccine.
Methods: This open, monocenter study in Australia inves-
tigated the effect of prior exposure to live-attenuated
ﬂavivirus vaccines on the safety, viremia and immunogenic-
ity of a recombinant, live attenuated tetravalent dengue
vaccine (TDV). TDV was given to subjects who were either:
ﬂavivirus na¨ıve, or had been randomized and vaccinated 1
year previously with yellow fever vaccine (YFV) or one of
two monovalent (serotype 1 or 2) live attenuated dengue
vaccines (MDV). Exposure to MDV was hypothesized to mim-
ick natural exposure. Adverse events, biological safety, and
dengue vaccine virus viremia (qRT-PCR) were assessed to
Day28. Neutralizing antibody levels against parental viruses
were assessed on D0 and 28 by PRNT50 assay. Subjects were
healthy adults aged 18—40.
Results: 35 subjects were enrolled and received TDV: 12
were ﬂavivus-na¨ıve, 8 had received YFV, 15 had received
MDV. Clinical or biological adverse reactions after TDV were
not more frequent or more severe among those previously
vaccinated with MDV or YFV, than among na¨ıve subjects. Vac-
cine virus viremia, predominantly serotype 4, was detected
on day 14 or 21 in 47% of MDV subjects, versus 88% of YF
subjects and 83% of na¨ıve subjects. After TDV vaccination,
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subjects previously exposed to MDV or YFV had higher neu-
tralizing responses than na¨ıve subjects.
Conclusions: Prior exposure to YF vaccination or live,
attenuated dengue vaccine virus, did not adversely affect
the safety and viremia proﬁle of a this recombinant, live
attenuated tetravalent dengue vaccine, and appeared to
increase immunogenicity.
doi:10.1016/j.ijid.2008.05.360
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Background and objectives: Haemophilus inﬂuenzae type
b (Hib) vaccination is not a routine immunization service in
Korea yet. This study was performed to estimate the disease
burden of Hib and the cost-beneﬁt of providing Hib vaccine
to children in Korea.
Method: We used the Rapid Assessment Tools (RATs) of
WHO to estimate the pre-vaccination Hib incidence and mor-
tality; one based on meningitis incidence in community and
the other based on under 5 year mortality statistics in 2004.
The fatality and sequelaes of Hib diseases were obtained
from multi-center based registry data. The direct and indi-
rect cost of Hib were calculated from the National Health
Insurance data (hospitalization and outpatient cost) in 2004,
National Health and Nutrition Survey(transport cost to hos-
pitals), Report of Ministry of Labor (indirect cost of work loss
and death) in 2004. Sensitivity analysis was done.
Results: The annual incidence of Hib meningitis was
10.8(95% CI: 3.8—15.0) per 100,000 children <5 years and
the case fatality rate was 6%. The average treatment cost
for an Hib meningitis case was about US $ 2,157. For a fatal
case, the average life time discounted economic loss was
about US $ 849,085. The Total annual cost of Hib diseases
was about US $ 42.5million. The break-even vaccine price,
where the annual vaccination costs equal annual Hib disease
burden averted was US $ 23.3 per dose in base case scenario
with 3% discount rate. In sensitivity analysis, due to the wide
conﬁdence interval of meningitis incidence rate, the burden
of Hib was from 15.9million to 58.6million.
Conclusion: In base case scenario, the routine Hib vacci-
nation to children would be cost-beneﬁt in Korea.
doi:10.1016/j.ijid.2008.05.361
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Background: In Taiwan, average inﬂuenza associated
mortality is approximately 4,500 per year. Inﬂuenza vacci-
nation is the most effective method to prevent inﬂuenza
infection and reduce its potentially severe complications.
In 1997, Taiwan launched the inﬂuenza vaccination cam-
paign. Since 1998, the government continually provides free
inﬂuenza vaccines to elderly aged 65 and above and other
high risk groups. The purpose of this article is to assess the
effectiveness of inﬂuenza vaccination in the elderly.
Method: For this retrospective observational study, vac-
cination coverage was collected through weekly based
reporting system and data regarding medical attendance
was retrieved from National Health Insurance databank from
1998 to 2007 inﬂuenza seasons. Medical attendance rate and
hospitalization rate was adjusted by age according to 2000
world standard.
Results: Inﬂuenza vaccination coverage among elderly
ranged from 9.9% to 68.4% with the peak in 2003. The annual
hospitalization rate (per 1,000 population) declined steadily
from 33.1 in 1998 to 28.8 in 2000, but rebounded slightly
from 30.8 in 2001 to 38.4 in 2005. The annual medical atten-
dance rate (per 1,000 population) declined from 202.2 in
1998 to 75.8 in 2006.The correlation analysis was height
relation (r = 0.7) between coverage and medical attendance
rat.
Conclusion: The declining medical attendance rate
attributes to vaccination upholds the inﬂuenza vaccination
program for the elderly. There is no evidence that inﬂuenza
vaccination is effective in reducing hospitalization in the
elderly. But it could be due to the National Health Insurance
confers full accessibility to the medical resources. As the
inﬂuenza vaccination coverage among elderly declines year
by year, a more aggressive and comprehensive educational
promotion strategy should be enhanced.
doi:10.1016/j.ijid.2008.05.362
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Nearly 4,500 persons die of inﬂuenza and related com-
plication yearly in Taiwan (20 /100,000 population), 80% of
them is 65 years or older. Policy of providing free inﬂuenza
vaccination for all people aged 65 and older started from
2001, but vaccination rates remained low with decreasing
trend. Understanding the relevant factors of inﬂuenza vac-
cination would be helpful for the vaccination strategy.
